U.S. Leisure Stock News

NYSE:HMN
NYSE:HMNInsurance

A Look At Horace Mann Educators (HMN) Valuation As Models Offer Mixed Signals

Stock performance snapshot Horace Mann Educators (HMN) has moved relatively quietly in recent weeks, with the stock edging up about 1% over the past month and about 4% over the past 3 months. For longer term holders, the stock shows a 9% total return over the past year and roughly 50% over the past 3 years, while year to date it is down about 1%. See our latest analysis for Horace Mann Educators. At a share price of $44.51, Horace Mann Educators has experienced some short-term share price...
NYSE:ECVT
NYSE:ECVTChemicals

Assessing Ecovyst (ECVT) Valuation After Stronger Quarterly Earnings And Buyback Completion

Stronger quarter and completed buyback put Ecovyst stock in focus Ecovyst (ECVT) has drawn fresh attention after first quarter 2026 results showed sales of US$214.95 million and a return to profitability, alongside completion of a multi year US$303.47 million share repurchase program. See our latest analysis for Ecovyst. The stronger first quarter and sizeable completed buyback appear to sit behind Ecovyst’s recent momentum, with a 90 day share price return of 26.25% and a 1 year total...
NasdaqGS:SBRA
NasdaqGS:SBRAHealth Care REITs

Is Higher Q1 Revenue And An Affirmed Dividend Altering The Investment Case For Sabra (SBRA)?

In April 2026, Sabra Health Care REIT, Inc. reported first-quarter results showing revenue of US$221.75 million and net income of US$40.88 million, alongside a slight year-on-year decrease in earnings per share from continuing operations to US$0.16. On the same day, the company also affirmed a quarterly dividend of US$0.30 per share, signaling ongoing cash returns to shareholders despite modest per‑share earnings pressure. Next, we’ll examine how Sabra’s higher quarterly revenue alongside...
NasdaqGS:COLL
NasdaqGS:COLLPharmaceuticals

A Look At Collegium Pharmaceutical (COLL) Valuation As Earnings Jump And AZSTARYS Acquisition Is Proposed

Collegium Pharmaceutical (COLL) is back in focus after reporting first quarter 2026 earnings that showed a sharp jump in profitability and progress across its ADHD and pain portfolios, alongside a proposed AZSTARYS acquisition. See our latest analysis for Collegium Pharmaceutical. Despite the strong first quarter earnings and the proposed AZSTARYS deal, Collegium Pharmaceutical’s share price performance has been mixed. The 7 day share price return was 9.31%, but the 90 day share price return...
NYSE:BLD
NYSE:BLDConsumer Durables

Did TopBuild’s (BLD) Profit Squeeze Amid Rising Sales Just Shift Its Investment Narrative?

TopBuild Corp. has already reported first-quarter 2026 results, with sales rising to US$1,445.86 million from US$1,233.28 million a year earlier, while net income decreased to US$104.81 million from US$123.39 million. The combination of higher revenue but lower net income and earnings per share highlights pressure on TopBuild’s profitability despite ongoing top-line growth. Next, we’ll examine how this mix of revenue growth and thinner earnings margins may influence TopBuild’s investment...
NasdaqGS:CSGP
NasdaqGS:CSGPReal Estate

Why CoStar Group (CSGP) Is Down 7.4% After Nasdaq-100 Exit And Reaffirmed 2026 Guidance

In the first quarter of 2026, CoStar Group reported US$897 million in sales versus US$732 million a year earlier, with net income improving to US$3 million from a US$15 million loss, while also confirming full-year 2026 revenue and earnings guidance. At the same time, CoStar is set to be removed from the Nasdaq-100 Index and is pressing ahead with its digital real estate expansion, including Homes.com and broader marketplace growth, even as insiders have recently committed US$6 million to...